DETAILED DRUG EVALUATION OF TREATMENT STRATEGIES

治疗策略的详细药物评估

• 批准号: 6033717
• 负责人: WILLIAM R WAUD
• 金额: $ 76.1万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-02-16 至 2000-02-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6033717
• 关键词: SCID mouse; antineoplastics; athymic mouse; disease /disorder model; dosage forms; drug administration routes; drug delivery systems; drug resistance; drug screening /evaluation; laboratory mouse; neoplasm /cancer chemotherapy; nonhuman therapy evaluation

The contractor shall evaluate compounds for anticancer activity in experimental in vivo tumor models. Studies shall focus on agents identified by the Program's disease-oriented in vitro drug screen, and shall employ human tumors growing in immune-deficient mice. Experiments shall be designed and conducted to optimize drug activity, and evaluate the drug's therapeutic potential.

承包商应评价化合物的抗癌活性， 实验体内肿瘤模型。 研究应侧重于代理人 通过该计划的疾病导向体外药物筛选确定， 应使用在免疫缺陷小鼠中生长的人肿瘤。 实验 应设计和实施以优化药物活性，并评价 药物的治疗潜力